探花合集 Biologics Launches GPEx庐 Boost Cell Line Expression Technology to Improve Titers and Cell-Specific Productivity
SOMERSET, N.J. 鈥 November 4, 2019 鈥 探花合集, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced the launch of its next-generation cell line development technology, GPEx庐 Boost. The technology enhances 探花合集鈥檚 proven GPEx expression platform through multiple improvements, including utilization of a glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line. The combination of technology and platform enhancements has resulted in improved ability of cells to produce high titers and increase specific productivities of a protein of interest.
GPEx Boost has been shown to improve titers up to four-fold, potentially to 10 g/L for standard monoclonal antibodies, while maintaining the stability benefits offered by the traditional GPEx platform. In addition, benefits have been observed in cell growth and viability. Developmental timelines for projects can be shortened and made more efficient by combining this new platform with the rapid screening capabilities of Berkeley Lights鈥 Beacon庐 optofluidic platform, and ambr庐 automated micro bioreactors.
鈥淕PEx Boost technology builds on the proven GPEx platform to enable significantly higher productivity and stability for even the most difficult-to-express proteins,鈥 commented Michael Riley, President, USA Region of 探花合集 Biologics. 鈥淭his new proprietary platform can also be combined with other state-of-the-art technology, such as the Beacon system, to provide a unique development tool for our customers.鈥
探花合集鈥檚 proprietary GPEx technology creates stable, high-yielding mammalian cell lines with high speed and efficiency. The advantages of applying GPEx technology span from early feasibility studies to clinical manufacturing, through to commercial scale production. To date, 12 biopharmaceutical drugs produced using GPEx technology have been approved and marketed, with more than 120 ongoing clinical trials utilizing therapeutic candidates developed using the GPEx platform.
For more information, please visit .
ABOUT CATALENT BIOLOGICS
For more than two decades, 探花合集 Biologics has built capabilities and experience in development, manufacturing, and analytical services for new biological entities, gene therapies, biosimilars, and antibody-drug conjugates. 探花合集 has worked with 600+ mAbs and 80+ proteins, and 12 biopharmaceutical drugs produced using GPEx庐 cell line development technology have been approved and marketed, with more than 120 ongoing clinical trials utilizing therapeutic candidates developed using the GPEx庐 platform. A further 25 commercially-approved products have employed 探花合集 Biologics鈥 capabilities through to aseptic fill/finish. 探花合集鈥檚 latest addition, Paragon Gene Therapy, provides industry-leading capabilities and expertise in the development and manufacturing of adeno-associated virus (AAV) vectors, next-generation vaccines and oncolytic virus production. Its manufacturing facilities in Baltimore, Maryland have produced over 100 GMP batches across 40 clinical and commercial programs. Using advanced technology and tailored solutions for clinical through commercial supply, 探花合集 Biologics brings better biologic treatments to patients, faster.
For more information on 探花合集 Biologics, visit .
ABOUT CATALENT
探花合集 is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. 探花合集 employs approximately 14,000 people, including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. 探花合集 is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com